High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone

Autor: Gary Cook, Glenn D. Flux, V. R. McCready, Alan Horwich, Francesca M. Buffa, J. Gadd, Robert Huddart, Joe M. O'Sullivan, David P. Dearnaley, A. R. Norman, Jennifer Treleaven, Sarah J. Chittenden, A. Al-Deen, K. Pomeroy, Matthew Guy
Rok vydání: 2002
Předmět:
Male
Cancer Research
Pathology
medicine.medical_specialty
Filgrastim
palliation
medicine.medical_treatment
Urology
Bone Neoplasms
Bone and Bones
Metastasis
Clinical
bone metastases
Prostate
Granulocyte Colony-Stimulating Factor
Organometallic Compounds
medicine
Carcinoma
Hormone replacement therapy (male-to-female)
Humans
Radionuclide Imaging
Radiotherapy
hormone refractory
business.industry
rhenium-186 HEDP
Hematopoietic Stem Cell Transplantation
Prostatic Neoplasms
Etidronic Acid
radionuclide therapy
Middle Aged
Prostate-Specific Antigen
prostate cancer
medicine.disease
Combined Modality Therapy
Hematopoietic Stem Cell Mobilization
Recombinant Proteins
Radiation therapy
Prostate-specific antigen
Rhenium
medicine.anatomical_structure
Oncology
Toxicity
Disease Progression
Stem cell
business
peripheral blood peripheral blood stem cell support
Zdroj: British Journal of Cancer
ISSN: 1532-1827
0007-0920
DOI: 10.1038/sj.bjc.6600348
Popis: We tested the feasibility and toxicity of high activities Rhenium-186 hydroxyethylidene diphosphonate, with peripheral blood stem cell rescue in patients with progressive hormone refractory prostate cancer metastatic to bone. Twenty-five patients received between 2500 and 5000 MBq of Rhenium-186 hydroxyethylidene diphosphonate followed 14 days later by the return of peripheral blood peripheral blood stem cells. Activity limiting toxicity was defined as grade III haematological toxicity, lasting at least 7 days, or grade IV haematological toxicity of any duration or any serious unexpected toxicity. Activity limiting toxicity occurred in two of six who received activities of 5000 MBq and maximum tolerated activity was defined at this activity level. Prostate specific antigen reductions of 50% or more lasting at least 4 weeks were seen in five of the 25 patients (20%) all of whom received more than 3500 MBq of Rhenium-186 hydroxyethylidene diphosphonate. The actuarial survival at 1 year is 54%. Administered activities of 5000 MBq of Rhenium-186 hydroxyethylidene diphosphonate are feasible using autologous peripheral blood peripheral blood stem cell rescue in patients with progressive hormone refractory prostate cancer metastatic to bone. The main toxicity is thrombocytopaenia, which is short lasting. A statistically significant activity/prostate specific antigen response was seen. We have now commenced a Phase II trial to further evaluate response rates. British Journal of Cancer (2002) 86, 1715–1720. doi:10.1038/sj.bjc.6600348 www.bjcancer.com © 2002 Cancer Research UK
Databáze: OpenAIRE
Externí odkaz: